Stifel reiterates Viavi Solutions stock rating citing AI portfolio By Investing.com

Viavi (VIAV) has surged 171% over the past year and trades at $31.44, approaching a 52-week high of $35.61. Stifel reiterated a Buy with a $35 price target and Needham raised its target to $36 after OFC 2026 meetings; seven analysts have recently revised earnings upward. The company launched multiple networking and test products (INX 700 probe microscope, DCX-700 24-fiber loss tester, TestCenter D2 1.6T appliance, Observer Threat Forensics, and AI-enabled distributed acoustic sensing) targeting AI networking, hyperscale data centers and aerospace & defense. InvestingPro flags the stock as currently overvalued versus its Fair Value, indicating valuation risk despite positive product and analyst momentum.

Analysis

Viavi sits at an inflection where product-led wins can convert into multi-year, high-margin service relationships with hyperscalers and defense customers, but the path is lumpy. Expect revenue recognition to be cadence-driven (large appliance and test-box shipments, followed by multi-quarter software/maintenance tails), which creates binary quarterly beats/misses even if the multi-year TAM is intact.

A key second-order effect: improved automated inspection and high-parallel test capability lowers per-unit cost for hyperscalers and silicon-photonics fabs, which will accelerate adoption of higher-margin optical components but also compress third-party lab-service revenue and create pricing pressure on commoditized handheld testers. That dynamic favors vendors that can sell integrated hardware+software subscriptions rather than one-off instruments.

Near-term upside is tied to continued hyperscaler capex and defense procurement cycles; downside is a tech-capex pause or inventory digestion at large customers. Watch book-to-bill, multi-year contract announcements, and backlog mix for signal — a sustained book-to-bill >1 should re-rate the stock, while any sequential backlog shrinkage will pressure multiples rapidly.

The market appears to be pricing a smooth transition from hardware sales into recurring software/security revenues; that is the biggest behavioral bet embedded in the multiple. If recurring attach rates lag or ASPs compress as customers demand integrated, lower-cost solutions, expect multiple contraction even with positive absolute revenue growth over 12–24 months.

Key Decisions for Investors

• Directional long (moderate risk): Buy VIAV Jan-2028 $30 LEAP calls (~2% portfolio notional). Rationale: captures multi-year optionality to AI networking and defense tails with capped premium. Exit/keystone: take 50% profits if shares +60% or if book-to-bill >1 for two consecutive quarters; cut loss at -60% of premium.
• Income-funded structured (balanced): Buy the same Jan-2028 $30 LEAPs and sell Sep-2026 $40 calls to finance ~30–40% of premium. This widens breakeven on multi-year appreciation while monetizing near-term IV. Risk: capped upside while retaining long-term exposure.
• Event play (short-term, higher conviction): If upcoming quarterly guide or a hyperscaler contract announcement is expected within 30–90 days, buy shares sized to 1–2% of portfolio and sell 30–60 day calls 10–15% OTM to generate carry. Use a 15% trailing stop and trim 30–50% into a confirmed contract announcement or sharp pop.
• Tail hedge (risk control): Buy VIAV 6–9 month puts ~10–15% OTM sized at 25–33% of equity position to protect against capex slowdowns or large order cancellations. This limits downside from rapid multiple compression while keeping long exposure intact.
• Monitoring triggers (non-trade): Add to longs if: two consecutive quarters of book-to-bill >1, backlog growth >20% YoY, or a multi-year defense contract announced. Trim/close if: sequential backlog decline, gross margin compression >300bps, or quoted ASP declines suggest pricing pressure.